Diagnostics rises after outlining Ebola test plan

Co-Diagnostics

19/05/2026 15:05

** Shares of diagnostics firm Co-Diagnostics CODX.O rise 78.83% to $2.45

** Co says it has completed a development strategy for a PCR test to detect Bundibugyo virus, which is causing an Ebola outbreak in the Democratic Republic of the Congo and Uganda

** Says it could rapidly deploy the test if needed, though its point-of-care PCR platform is still under regulatory review and not yet approved

** The update follows a World Health Organization emergency declaration and enhanced U.S. CDC screening measures for travelers from affected regions

** Says rapid PCR testing can help identify cases and improve real-time tracking and containment of outbreaks

** Including session's move, CODX down 58.5% YTD

(Reporting by Kunal Das in Bengaluru)

((Kunal.Das2@thomsonreuters.com;))